Meeting
2013 ASCO Annual Meeting
POWER: An open-label, randomized phase III trial of cisplatin and 5-FU with or without panitumumab (P) for patients (pts) with nonresectable, advanced, or metastatic esophageal squamous cell cancer (ESCC).
Authors
Markus Hermann Moehler
Johannes Gutenberg University Mainz, Mainz, Germany
Markus Hermann Moehler , Ingo Ringshausen , Ralf Hofheinz , Salah-Eddin Al-Batran , Lothar Mueller , Peter C. Thuss-Patience , Kersten Borchert , Aysun Karatas , Ralph Keller , Anja Klein , Anne Kranich , Baruch Brenner , Sylvie Lorenzen , Manfred P. Lutz , Richard Greil , Josep Tabernero , Eric Van Cutsem , Ullrich Graeven
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT01627379
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS4158)
DOI
10.1200/jco.2013.31.15_suppl.tps4158
Abstract #
TPS4158
Poster Bd #
33D
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER).
First Author: Markus H. Moehler
Poster
2022 ASCO Gastrointestinal Cancers Symposium
LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma.
First Author: Jong-Mu Sun
Poster
2019 Gastrointestinal Cancers Symposium
A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.
First Author: Ursula Wiedermann
Poster
2017 ASCO Annual Meeting
Nimotuzumab combined with cisplatin plus fluorouracil chemotherapy in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: A multicentre, open-label, phase II clinical trial.
First Author: Chong Zhao